S. Bui

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Félix Ratjen, Christopher Hug, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2017 · 291 citations

Pulmonary Fibrosis, Medicine, Placebo-controlled Phase 3

Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

Pierre‐Régis Burgel, I. Durieu, R. Chiron et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 227 citations

Integrated control of appetite and fat metabolism by the leptin-proopiomelanocortin pathway

Stacy Forbes, S. Bui, Brian R. Robinson et al. · Proceedings of the National Academy of Sciences · 2001 · 154 citations · Full text

Nutrition, Metabolic Rate, Leptin-proopiomelanocortin Pathway +19

Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis

Pierre‐Régis Burgel, À. Munck, I. Durieu et al. · American Journal of Respiratory and Critical Care Medicine · 2019 · 127 citations

Premenstrual Syndrome (PMS) in Adolescents: Severity and Impairment

Michelle Vichnin, Ellen W. Freeman, Hui Lin et al. · Journal of Pediatric and Adolescent Gynecology · 2006 · 97 citations

Psychiatry, Gynecology, Adolescent Development +5